Zydus Lifesciences reports strong Q3 and 9M FY26 financial performance

New Delhi: Zydus Lifesciences Ltd. reported robust growth in its unaudited consolidated results for the quarter and nine months ended December 31, 2025.

In Q3 FY26, revenue from operations rose 30% year-on-year to ₹68,645 million, while EBITDA grew 31% to ₹18,164 million, with margins improving to 26.5%. Adjusted net profit for the quarter stood at ₹11,109 million, up 9% YoY, supported by continued investments in research and development, which accounted for 8.8% of revenues.

For the nine-month period, revenue reached ₹195,614 million, marking a 17% increase, while EBITDA rose 20% to ₹59,207 million with margins improving to 30.3%. Adjusted net profit grew 15% to ₹38,640 million, reflecting steady performance across core businesses.

Growth was driven primarily by the pharmaceutical business, including strong performance in India formulations, North America formulations, and international markets, alongside significant expansion in the consumer wellness segment, which more than doubled year-on-year following the consolidation of Comfort Click Limited.

During the quarter, the company also strengthened its innovation and specialty portfolio through new product launches in the U.S. generics market, regulatory progress in biosimilars and vaccines, and expansion in MedTech and biologics manufacturing capabilities.

Commenting on the results, Managing Director Dr. Sharvil Patel said the company’s performance reflects the scalability of its core businesses, disciplined M&A strategy, and continued focus on patient-centric innovation, compliance, and supply-chain agility.